Drug Profile
DC 159A
Alternative Names: DC-159; DC-159aLatest Information Update: 15 May 2008
Price :
$50
*
At a glance
- Originator Daiichi Sankyo Company
- Class
- Mechanism of Action DNA gyrase inhibitors; DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bacterial infections; Community-acquired pneumonia; Tuberculosis
Most Recent Events
- 13 May 2008 Discontinued - Phase-I for Bacterial infections in European Union (PO)
- 13 May 2008 Discontinued - Phase-I for Bacterial infections in Japan (PO)
- 13 May 2008 Discontinued - Phase-I for Bacterial infections in USA (PO)